MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, FENCF had -$4,687K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$4,687K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
Net (loss)/income
-4,954
Inventory reserve
-517
Allowance for credit losses
67
Amortization of debt discount
38
Loss on securities
2
Amortization of norgine asset
77
Stock-based compensation - employees
4,511
Accounts receivable
8,982
Prepaid expenses
-1,681
Inventory
1,417
Other assets
-85
Accounts payable
2,625
Accrued liabilities
273
Net cash (used in) / provided by operating activities
-6,511
Issuance of shares, options exercise
1,985
Cash paid for taxes on restricted share release
161
Net cash provided by / (used in) financing activities
1,824
(decrease) / increase in cash and cash equivalents
-4,687
Cash and cash equivalents at beginning of period
26,634
Cash and cash equivalents at end of period
21,947
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

FENNEC PHARMACEUTICALS INC. (FENCF)

FENNEC PHARMACEUTICALS INC. (FENCF)